1. Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine
- Author
-
Santiago T, DeVaux RS, Kurzatkowska K, Espinal R, Herschkowitz JI, and Hepel M
- Subjects
d drug delivery ,Raman spectroscopic nanocarrier testing ,Flow cytometry ,Controlled drug release ,Breast cancer cells ,Gemcitabine ,Doxorubicin ,Folate receptor targeting ,Medicine (General) ,R5-920 - Abstract
Ty Santiago,1 Rebecca Sinnott DeVaux,2 Katarzyna Kurzatkowska,1 Ricardo Espinal,1 Jason I Herschkowitz,2 Maria Hepel1 1Department of Chemistry, State University of New York at Potsdam, Potsdam, 2Department of Biomedical Sciences, Cancer Research Center, University at Albany, State University of New York, Rensselaer, NY, USA Abstract: Advanced and metastatic cancer forms are extremely difficult to treat and require high doses of chemotherapeutics, inadvertently affecting also healthy cells. As a result, the observed survival rates are very low. For instance, gemcitabine (GEM), one of the most effective chemotherapeutic drugs used for the treatment of breast and pancreatic cancers, sees only a 20% efficacy in penetrating cancer tissue, resulting in
- Published
- 2017